

# Christina Ochsenbauer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7739345/publications.pdf>

Version: 2024-02-01

50  
papers

3,035  
citations

236925

25  
h-index

182427

51  
g-index

51  
all docs

51  
docs citations

51  
times ranked

4188  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4 <sup>+</sup> T Cell. <i>Journal of Virology</i> , 2022, 96, jvi0192921.	3.4	10
2	Characterization of Near Full-Length Transmitted/Founder HIV-1 Subtype D and A/D Recombinant Genomes in a Heterosexual Ugandan Population (2006–2011). <i>Viruses</i> , 2022, 14, 334.	3.3	4
3	Innate immune regulation in HIV latency models. <i>Retrovirology</i> , 2022, 19, .	2.0	3
4	Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. <i>Viruses</i> , 2021, 13, 1472.	3.3	8
5	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes. <i>Journal of Virology</i> , 2021, 95, e0016021.	3.4	4
6	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17
7	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. <i>Journal of Virology</i> , 2021, , JVI0164321.	3.4	7
8	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , 2021, 17, e1010046.	4.7	6
9	Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set. <i>PLoS ONE</i> , 2021, 16, e0260118.	2.5	6
10	Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit. <i>Journal of Infection</i> , 2020, 80, 210-218.	3.3	5
11	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. <i>Nature Communications</i> , 2020, 11, 1767.	12.8	15
12	Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	104
13	Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression. <i>Journal of Virology</i> , 2019, 93, .	3.4	21
14	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. <i>Frontiers in Immunology</i> , 2019, 10, 2875.	4.8	20
15	Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. <i>PLoS Pathogens</i> , 2019, 15, e1008161.	4.7	19
16	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	11.0	124
17	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Virology</i> , 2018, 92, .	3.4	56
18	Neutrophil extracellular traps prevent HIV infection in the female genital tract. <i>Mucosal Immunology</i> , 2018, 11, 1420-1428.	6.0	72

#	ARTICLE	IF	CITATIONS
19	CD4 regulatory T cells augment HIV-1 expression of polarized M1 and M2 monocyte derived macrophages. <i>Virology</i> , 2017, 504, 79-87.	2.4	12
20	Characterization of immune cells and infection by HIV in human ovarian tissues. <i>American Journal of Reproductive Immunology</i> , 2017, 78, e12687.	1.2	12
21	Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. <i>Cell Reports</i> , 2017, 20, 984-998.	6.4	66
22	Potent <i>In Vivo</i> NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. <i>Journal of Virology</i> , 2017, 91, .	3.4	31
23	Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells. <i>PLoS Pathogens</i> , 2017, 13, e1006163.	4.7	51
24	The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria. <i>PLoS Pathogens</i> , 2017, 13, e1006226.	4.7	28
25	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	6.1	47
26	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016, 90, 5315-5328.	3.4	12
27	Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys. <i>Journal of Virology</i> , 2016, 90, 8795-8808.	3.4	1
28	High-Throughput Humanized Mouse Models for Evaluation of HIV-1 Therapeutics and Pathogenesis. <i>Methods in Molecular Biology</i> , 2016, 1354, 221-235.	0.9	7
29	Optimized Replicating <i>Renilla</i> Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1278-1296.	1.1	26
30	The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment. <i>Journal of Virology</i> , 2015, 89, 9559-9570.	3.4	13
31	<i>In Vivo</i> Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute <i>In Vivo</i> HIV-1 Infection in Humanized Mice. <i>Journal of Virology</i> , 2015, 89, 6264-6274.	3.4	78
32	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	3.4	55
33	Potent Functional Antibody Responses Elicited by HIV-1 DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. <i>PLoS ONE</i> , 2015, 10, e0118486.	2.5	42
34	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. <i>Cell Host and Microbe</i> , 2014, 16, 711-721.	11.0	143
35	Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. <i>Journal of Translational Medicine</i> , 2014, 12, 346.	4.4	14
36	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 2489-2507.	3.4	274

#	ARTICLE	IF	CITATIONS
37	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. <i>Journal of Cell Biology</i> , 2014, 206, 867-876.	5.2	28
38	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. <i>Journal of Immunological Methods</i> , 2014, 409, 161-173.	1.4	28
39	Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. <i>Journal of Immunological Methods</i> , 2014, 409, 147-160.	1.4	39
40	Relative resistance of HIV-1 founder viruses to control by interferon-alpha. <i>Retrovirology</i> , 2013, 10, 146.	2.0	183
41	Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A New Model for Investigating HIV-1 Transmission and Treatment Efficacy. <i>PLoS ONE</i> , 2013, 8, e63537.	2.5	31
42	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13540-13545.	7.1	73
43	Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus. <i>Journal of Virology</i> , 2013, 87, 890-899.	3.4	23
44	Phenotypic properties of transmitted founder HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6626-6633.	7.1	379
45	Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. <i>Journal of Virology</i> , 2012, 86, 2715-2728.	3.4	291
46	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. <i>Journal of Virology</i> , 2011, 85, 7029-7036.	3.4	210
47	Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. <i>Virology</i> , 2010, 408, 1-13.	2.4	169
48	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. <i>Journal of Virology</i> , 2010, 84, 4998-5006.	3.4	110
49	Uterine Epithelial Cell Regulation of DC-SIGN Expression Inhibits Transmitted/Founder HIV-1 Trans Infection by Immature Dendritic Cells. <i>PLoS ONE</i> , 2010, 5, e14306.	2.5	33
50	New virologic reagents for neutralizing antibody assays. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 418-425.	3.8	24